PLK1 and neoplasm: Suffian et al. reported that engineered HBc-VLPs targeting HER2 expressing on the surface of cancer cells can carry siRNA to knock down the polo-like kinase 1 (PLK1) gene in cultured cancer cells, thereby inducing death of the tumor cells [47].